Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya Sells 202,146 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 202,146 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $54.29, for a total transaction of $10,974,506.34. Following the completion of the sale, the director now directly owns 208,742 shares in the company, valued at $11,332,603.18. This trade represents a 49.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Mona Ashiya also recently made the following trade(s):

• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total transaction of $4,529,259.90.

Disc Medicine Stock Up 0.1 %

Shares of NASDAQ IRON opened at $53.93 on Thursday. The firm’s 50-day simple moving average is $56.62 and its 200 day simple moving average is $55.94. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -13.55 and a beta of 0.73. Disc Medicine, Inc. has a 12-month low of $25.60 and a 12-month high of $68.86.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.08. On average, equities analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC lifted its position in Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after buying an additional 266 shares in the last quarter. Teacher Retirement System of Texas lifted its position in Disc Medicine by 8.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company’s stock valued at $308,000 after purchasing an additional 396 shares during the period. Sterling Capital Management LLC lifted its position in Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after purchasing an additional 503 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Disc Medicine by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock valued at $400,000 after purchasing an additional 593 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new position in Disc Medicine during the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Wall Street Analyst Weigh In

IRON has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $118.00 price target on shares of Disc Medicine in a report on Tuesday, January 21st. Scotiabank boosted their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. Stifel Nicolaus boosted their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Morgan Stanley restated an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. Finally, TD Cowen started coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating on the stock. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $89.10.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.